Secondary motoneurons in juvenile and adult zebrafish: axonal pathfinding errors caused by embryonic nicotine exposure.
Nicotine is a drug of abuse that has been reported to have many adverse effects on the developing nervous system. We previously demonstrated that embryonic exposure to nicotine alters axonal pathfinding of spinal secondary motoneurons in zebrafish. We hypothesize that these changes will persist into adulthood. The Tg(isl1:GFP) line of zebrafish, which expresses green fluorescent protein (GFP) in a subtype of spinal secondary motoneurons, was used to investigate potential long-term consequences of nicotine exposure on motoneuron development. Anatomical characterization of Tg(isl1:GFP) zebrafish ranging between 3 and 30 days postfertilization (dpf) was initially performed in fixed tissue to characterize axonal trajectories in larval and juvenile fish. Tg(isl1:GFP) embryos were transiently exposed to 5-30 microM nicotine. They were then rescued from nicotine and raised into later stages of life (3-30 dpf) and fixed for microscopic examination. Morphological analysis revealed that nicotine-induced abnormalities in secondary motoneuron anatomy were still evident in juvenile fish. Live imaging of Tg(isl1:GFP) zebrafish using fluorescent stereomicroscopy revealed that the nicotine-induced changes in motoneuron axonal pathfinding persisted into adulthood. We detected abnormalities in 37-dpf fish that were transiently exposed to nicotine as embryos. These fish were subsequently imaged over a 7-week period of time until they were approximately 3 months of age. These pathfinding errors of spinal secondary motoneuron axons detected at 37 dpf persisted within the same fish until 86 dpf, the latest age analyzed. These findings indicate that exposure to nicotine during embryonic development can have permanent consequences for motoneuron anatomy in zebrafish.
Menelaou
Evdokia
E
Department of Biological Sciences, Louisiana State University, Baton Rouge, Louisiana 70803, USA.
Svoboda
Kurt R
KR
D000818:Animals; D030801:Animals, Genetically Modified; D001369:Axons / Q000187:drug effects* / Q000502:physiology / Q000648:ultrastructure*; D002465:Cell Movement / Q000187:drug effects / Q000502:physiology; D004625:Embryo, Nonmammalian / Q000033:anatomy & histology / Q000187:drug effects* / Q000502:physiology; D049452:Green Fluorescent Proteins / Q000235:genetics / Q000378:metabolism; D009046:Motor Neurons / Q000166:cytology* / Q000187:drug effects* / Q000502:physiology; D009469:Neuromuscular Junction / Q000648:ultrastructure; D009538:Nicotine / Q000494:pharmacology*; D018722:Nicotinic Agonists / Q000494:pharmacology; D015027:Zebrafish / Q000033:anatomy & histology / Q000254:growth & development
D018722:Nicotinic Agonists; D049452:Green Fluorescent Proteins; D009538:Nicotine